Cellectis S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,559.00
112,997.00
314,238.00
276,216.00
247,320.10
395,301.60
Total Accounts Receivable
11,379.00
16,153.00
15,598.00
13,239.00
12,236.80
19,303.70
Inventories
367.00
135.00
158.00
112.00
208.20
240.60
Other Current Assets
639.00
2,072.00
4,224.00
6,892.00
9,406.20
11,730.70
Total Current Assets
19,944.00
131,357.00
334,218.00
296,459.00
269,171.40
426,576.60
Net Property, Plant & Equipment
3,869.00
2,610.00
5,043.00
16,033.00
6,017.70
8,783.60
Total Investments and Advances
435.00
577.00
845.00
656.00
836.10
1,653.30
Long-Term Note Receivable
-
1,400.00
-
-
-
-
Intangible Assets
4,627.00
1,026.00
956.00
1,274.00
1,191.70
1,109.20
Other Assets
-
644.00
-
-
-
-
Total Assets
28,875.00
137,614.00
341,062.00
314,422.00
277,216.90
438,122.70
ST Debt & Current Portion LT Debt
691.00
862.00
1,921.00
1,641.00
17.50
Accounts Payable
9,700.00
9,802.00
6,611.00
9,223.00
7,878.10
Income Tax Payable
1,302.00
294.00
6,314.00
182.00
-
Other Current Liabilities
10,853.00
63,907.00
62,094.00
42,242.00
28,358.60
Total Current Liabilities
22,546.00
74,865.00
76,940.00
53,288.00
36,254.20
Long-Term Debt
3,375.00
2,824.00
66.00
28.00
10.80
Provision for Risks & Charges
437.00
398.00
437.00
532.00
2,857.30
Total Liabilities
26,358.00
78,087.00
77,443.00
53,848.00
39,122.30
Common Equity (Total)
2,740.00
60,786.00
262,894.00
258,795.00
222,177.70
Total Shareholders' Equity
2,740.00
60,786.00
262,894.00
258,795.00
222,177.70
Total Equity
2,517.00
59,527.00
263,619.00
260,574.00
238,094.60
Liabilities & Shareholders' Equity
28,875.00
137,614.00
341,062.00
314,422.00
277,216.90
Accumulated Minority Interest
223.00
1,259.00
725.00
1,779.00
15,916.90

About Cellectis

View Profile
Address
8, rue de la Croix Jarry
Paris Ile-de-France 75013
France
Employees -
Website http://www.cellectis.com
Updated 07/08/2019
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases.